HIV-1–specific immune responses in subjects who temporarily contain virus replication after discontinuation of highly active antiretroviral therapy
Open Access
- 15 September 1999
- journal article
- Published by American Society for Clinical Investigation in Journal of Clinical Investigation
- Vol. 104 (6) , R13-R18
- https://doi.org/10.1172/jci7371
Abstract
Therapeutic intervention with highly active antiretroviral therapy (HAART) can lead to suppression of HIV-1 plasma viremia to undetectable levels for 3 or more years. However, adherence to complex drug regimens can prove problematic, and subjects may temporarily discontinue HAART for variable periods. We studied 6 HIV-1–infected individuals who stopped therapy. Off HAART, levels of viremia were suppressed to fewer than 500 copies/mL in 2 subjects for more than 12 and more than 24 months, respectively, and in 1 subject for 4 months on 1 occasion. Three subjects failed to contain plasma viremia. Broad and strong HIV-1–specific immune responses were detected in subjects with prolonged suppression of viral replication. This longitudinal study suggests that containment of HIV-1 replication to low or undetectable levels after discontinuation of HAART is associated with strong virus-specific immune responses. Boosting of HIV-1–specific immune responses should be considered as an adjunctive treatment strategy for HIV-1–infected individuals on HAART.Keywords
This publication has 31 references indexed in Scilit:
- Persistence of HIV-1 Transcription in Peripheral-Blood Mononuclear Cells in Patients Receiving Potent Antiretroviral TherapyNew England Journal of Medicine, 1999
- Quantifying Residual HIV-1 Replication in Patients Receiving Combination Antiretroviral TherapyNew England Journal of Medicine, 1999
- Molecular tracking of an Human Immunodeficiency Virus nef specific cytotoxic T-cell clone shows persistence of clone-specific T-cell receptor DNA but not mRNA following early combination antiretroviral therapyImmunology Letters, 1999
- The Effect of Commencing Combination Antiretroviral Therapy Soon after Human Immunodeficiency Virus Type 1 Infection on Viral Replication and Antiviral Immune ResponsesThe Journal of Infectious Diseases, 1999
- Longitudinal and Cross‐Sectional Analysis of Cytotoxic T Lymphocyte Responses and Their Relationship to Vertical Human Immunodeficiency Virus TransmissionThe Journal of Infectious Diseases, 1998
- HIV-1 Antigen–specific and –nonspecific B Cell Responses Are Sensitive to Combination Antiretroviral TherapyThe Journal of Experimental Medicine, 1998
- Quantitation of HIV-1-Specific Cytotoxic T Lymphocytes and Plasma Load of Viral RNAScience, 1998
- RETRACTED: Characterization of long-term survivors of human immunodeficiency virus type 1 infectionImmunology Letters, 1996
- Restricted antigenic variability of the epitope recognized by the neutralizing gp41 antibody 2F5AIDS, 1996
- Prognosis in HIV-1 Infection Predicted by the Quantity of Virus in PlasmaScience, 1996